232 related articles for article (PubMed ID: 19738042)
1. Glomus tumors in neurofibromatosis type 1: genetic, functional, and clinical evidence of a novel association.
Brems H; Park C; Maertens O; Pemov A; Messiaen L; Upadhyaya M; Claes K; Beert E; Peeters K; Mautner V; Sloan JL; Yao L; Lee CC; Sciot R; De Smet L; Legius E; Stewart DR
Cancer Res; 2009 Sep; 69(18):7393-401. PubMed ID: 19738042
[TBL] [Abstract][Full Text] [Related]
2. Mitotic recombination of chromosome arm 17q as a cause of loss of heterozygosity of NF1 in neurofibromatosis type 1-associated glomus tumors.
Stewart DR; Pemov A; Van Loo P; Beert E; Brems H; Sciot R; Claes K; Pak E; Dutra A; Lee CC; Legius E
Genes Chromosomes Cancer; 2012 May; 51(5):429-37. PubMed ID: 22250039
[TBL] [Abstract][Full Text] [Related]
3. Glomus tumors in individuals with neurofibromatosis type 1.
Kumar MG; Emnett RJ; Bayliss SJ; Gutmann DH
J Am Acad Dermatol; 2014 Jul; 71(1):44-8. PubMed ID: 24685357
[TBL] [Abstract][Full Text] [Related]
4. Multiple glomus tumors and segmental neurofibromatosis: there are no coincidences.
Cabral R; Santiago F; Tellechea O
Dermatol Online J; 2011 Mar; 17(3):4. PubMed ID: 21426870
[TBL] [Abstract][Full Text] [Related]
5. TAGLN expression is upregulated in NF1-associated malignant peripheral nerve sheath tumors by hypomethylation in its promoter and subpromoter regions.
Park GH; Lee SJ; Yim H; Han JH; Kim HJ; Sohn YB; Ko JM; Jeong SY
Oncol Rep; 2014 Oct; 32(4):1347-54. PubMed ID: 25109740
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis, management, and complications of glomus tumours of the digits in neurofibromatosis type 1.
Stewart DR; Sloan JL; Yao L; Mannes AJ; Moshyedi A; Lee CC; Sciot R; De Smet L; Mautner VF; Legius E
J Med Genet; 2010 Aug; 47(8):525-32. PubMed ID: 20530151
[TBL] [Abstract][Full Text] [Related]
7. Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice.
Sharma R; Wu X; Rhodes SD; Chen S; He Y; Yuan J; Li J; Yang X; Li X; Jiang L; Kim ET; Stevenson DA; Viskochil D; Xu M; Yang FC
Hum Mol Genet; 2013 Dec; 22(23):4818-28. PubMed ID: 23863460
[TBL] [Abstract][Full Text] [Related]
8. The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas.
Pemov A; Li H; Patidar R; Hansen NF; Sindiri S; Hartley SW; Wei JS; Elkahloun A; Chandrasekharappa SC; ; Boland JF; Bass S; ; Mullikin JC; Khan J; Widemann BC; Wallace MR; Stewart DR
Oncogene; 2017 Jun; 36(22):3168-3177. PubMed ID: 28068329
[TBL] [Abstract][Full Text] [Related]
9. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
10. [Characterization of the neurofibromatosis type 1 gene and neurofibromin's role in cells].
Sakai A
Nihon Rinsho; 2000 Jul; 58(7):1426-9. PubMed ID: 10921317
[TBL] [Abstract][Full Text] [Related]
11. Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway.
Feldkamp MM; Angelov L; Guha A
Surg Neurol; 1999 Feb; 51(2):211-8. PubMed ID: 10029430
[TBL] [Abstract][Full Text] [Related]
12. Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis.
Laycock-van Spyk S; Thomas N; Cooper DN; Upadhyaya M
Hum Genomics; 2011 Oct; 5(6):623-90. PubMed ID: 22155606
[TBL] [Abstract][Full Text] [Related]
13. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma.
Lau N; Feldkamp MM; Roncari L; Loehr AH; Shannon P; Gutmann DH; Guha A
J Neuropathol Exp Neurol; 2000 Sep; 59(9):759-67. PubMed ID: 11005256
[TBL] [Abstract][Full Text] [Related]
14. Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1.
Rutkowski JL; Wu K; Gutmann DH; Boyer PJ; Legius E
Hum Mol Genet; 2000 Apr; 9(7):1059-66. PubMed ID: 10767330
[TBL] [Abstract][Full Text] [Related]
15. Toward a survey of somatic mutation of the NF1 gene in benign neurofibromas of patients with neurofibromatosis type 1.
Eisenbarth I; Beyer K; Krone W; Assum G
Am J Hum Genet; 2000 Feb; 66(2):393-401. PubMed ID: 10677298
[TBL] [Abstract][Full Text] [Related]
16. Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.
Paria N; Cho TJ; Choi IH; Kamiya N; Kayembe K; Mao R; Margraf RL; Obermosser G; Oxendine I; Sant DW; Song MH; Stevenson DA; Viskochil DH; Wise CA; Kim HK; Rios JJ
J Bone Miner Res; 2014 Dec; 29(12):2636-42. PubMed ID: 24932921
[TBL] [Abstract][Full Text] [Related]
17. A mouse embryonic stem cell model of Schwann cell differentiation for studies of the role of neurofibromatosis type 1 in Schwann cell development and tumor formation.
Roth TM; Ramamurthy P; Ebisu F; Lisak RP; Bealmear BM; Barald KF
Glia; 2007 Aug; 55(11):1123-33. PubMed ID: 17597122
[TBL] [Abstract][Full Text] [Related]
18. Biallelic NF1 inactivation in high grade serous ovarian cancers from patients with neurofibromatosis type 1.
Courtney E; Chan SH; Li ST; Ishak D; Merchant K; Shaw T; Chay WY; Chin FHX; Wong WL; Wong A; Ngeow J
Fam Cancer; 2020 Oct; 19(4):353-358. PubMed ID: 32405727
[TBL] [Abstract][Full Text] [Related]
19. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis.
McGillicuddy LT; Fromm JA; Hollstein PE; Kubek S; Beroukhim R; De Raedt T; Johnson BW; Williams SM; Nghiemphu P; Liau LM; Cloughesy TF; Mischel PS; Parret A; Seiler J; Moldenhauer G; Scheffzek K; Stemmer-Rachamimov AO; Sawyers CL; Brennan C; Messiaen L; Mellinghoff IK; Cichowski K
Cancer Cell; 2009 Jul; 16(1):44-54. PubMed ID: 19573811
[TBL] [Abstract][Full Text] [Related]
20. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors.
Dasgupta B; Yi Y; Chen DY; Weber JD; Gutmann DH
Cancer Res; 2005 Apr; 65(7):2755-60. PubMed ID: 15805275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
